Abstract

BackgroundSerum biomarkers, such as serum creatinine (SCr) and serum cystatin C (SCysC), have been widely used to evaluate renal function in patients who have chronic kidney disease (CKD).ObjectiveThis article aims to assess the value of determining SCr and SCysC levels in patients that have long-term kidney disease. Approaches: MEDLINE, EmBase, the Cochrane Library and other databases were searched using both MeSH terms and text words to collect research that assessed the diagnostic value of using SCr and SCysC to evaluate Glomerular Filtration Rate (GFR) in patients with CKD. Data were converted into fourfold tables. Summary Receiver Operating Characteristic Curves and meta-analyses were accomplished via Meta-Disc version 1.4.ResultsIn total, 21 relevant articles involving 3112 study subjects were included in our review. Results showed that the collective sensitivity for SCr and SCysC was 0.77 (95% CI: 0.69–0.84) and 0.87 (95% CI: 0.82–0.91), respectively. The pooled specificity for SCr and SCysC was 0.91 (95% CI: 0.86–0.94) and 0.87 (95% CI: 0.82–0.91), respectively. Subgroup analyses demonstrated that when GFR cut-off values are set to 60 (ml/min/1.73 m2), the pooled sensitivity is 0.94 (95% CI: 0.90–0.96) for SCysC and 0.75 (95% CI: 0.68–0.82) for SCr.ConclusionsThe diagnostical accuracy for impaired kidney function favors SCysC. Confidence intervals for the pooled sensitivity and specificity for SCr and SCysC overlap. However, SCysC is more sensitive for estimating GFR than SCr when GFR cut-off values are set to 60 (ml/min/1.73 m2).

Highlights

  • chronic kidney disease (CKD), as well as end stage renal disease (ESRD), presents serious risks to human health

  • Results showed that the collective sensitivity for serum creatinine (SCr) and serum cystatin C (SCysC) was 0.77 and 0.87, respectively

  • Subgroup analyses demonstrated that when Glomerular Filtration Rate (GFR) cutoff values are set to 60, the pooled sensitivity is 0.94 for SCysC and 0.75 for SCr

Read more

Summary

Introduction

CKD, as well as end stage renal disease (ESRD), presents serious risks to human health. Early stage prognosis of CKD is required for early initiation of treatment to help patients, in particular, those at greatest risk for progression. GFR is regarded as a significant indicator for kidney surgery, and this measurement is considered to be the gold standard for evaluating renal disease. GFR acts as an important indicator in the diagnosis of patients, as well as in clinical management. Serum biomarkers, such as serum creatinine (SCr) and serum cystatin C (SCysC), have been widely used to evaluate renal function in patients who have chronic kidney disease (CKD)

Methods
Results
Discussion
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call